MX2015013915A - Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. - Google Patents
Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.Info
- Publication number
- MX2015013915A MX2015013915A MX2015013915A MX2015013915A MX2015013915A MX 2015013915 A MX2015013915 A MX 2015013915A MX 2015013915 A MX2015013915 A MX 2015013915A MX 2015013915 A MX2015013915 A MX 2015013915A MX 2015013915 A MX2015013915 A MX 2015013915A
- Authority
- MX
- Mexico
- Prior art keywords
- halogen
- lower alkyl
- cyano
- disease
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula general I: (ver formula) en la que: R1 es halógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno o ciano; R2 es hidrógeno, CF3 o alquilo inferior; R3 es hidrógeno, alquilo inferior, alquenilo inferior, alquinilo inferior, heterocicloalquilo, alquilo inferior sustituido por ciano, ciano, bencilo sustituido por halógeno, 2-oxa-6-aza-espiro[3.3]hept-6-ilo o es alcoxi inferior sustituido por halógeno; X es -CH2- o -CH2-CH2-; o a una sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero correspondiente y/o sus isómeros ópticos. Los compuestos pueden utilizarse para el tratamiento de la esquizofrenia, el trastorno de personalidad obsesivo-compulsivo, la depresión mayor, los trastornos bipolares, los trastornos de ansiedad, el envejecimiento normal, la epilepsia, la degeneración retinal, la lesión cerebral traumática, la lesión de la médula espinal, el trastorno de estrés post-traumático, el trastorno de pánico, la enfermedad de Parkinson, la demencia, la enfermedad de Alzheimer, el desequilibrio cognitivo moderado, la disfunción cognitiva inducida por la quimioterapia, el síndrome de Down, los trastornos del espectro autista, la pérdida de audición, el tintineo, la ataxia espinocerebelar, la esclerosis lateral amiotrófica, la esclerosis múltiple, la enfermedad de Huntington, la apoplejía, los trastornos debidos a la terapia de radiación, el estrés crónico, el abuso de drogas neuroactivas, por ejemplo el alcohol, opiáceos, metanfetamina, fenciclidina o cocaína.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161949 | 2013-04-02 | ||
| PCT/EP2014/056393 WO2014161801A1 (en) | 2013-04-02 | 2014-03-31 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013915A true MX2015013915A (es) | 2015-12-11 |
Family
ID=47997284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013915A MX2015013915A (es) | 2013-04-02 | 2014-03-31 | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9586966B2 (es) |
| EP (1) | EP2981538B1 (es) |
| JP (1) | JP6212623B2 (es) |
| KR (1) | KR101767329B1 (es) |
| CN (1) | CN105246895B (es) |
| AR (1) | AR095970A1 (es) |
| BR (1) | BR112015020179A2 (es) |
| CA (1) | CA2905270C (es) |
| HK (1) | HK1213553A1 (es) |
| MX (1) | MX2015013915A (es) |
| RU (1) | RU2628126C2 (es) |
| TW (1) | TW201443056A (es) |
| WO (1) | WO2014161801A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX362184B (es) * | 2012-08-06 | 2019-01-08 | Hoffmann La Roche | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4927198B1 (es) * | 1968-06-05 | 1974-07-16 | ||
| US3867374A (en) * | 1968-06-05 | 1975-02-18 | Mcneilab Inc | Diazepinoindoles |
| US3689503A (en) * | 1970-07-30 | 1972-09-05 | Mcneilab Inc | Indole-2-carboxylates |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| CA2631128A1 (en) * | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| US20090192147A1 (en) * | 2008-01-30 | 2009-07-30 | Wyeth | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
| JP6126528B2 (ja) | 2010-07-07 | 2017-05-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ | 神経新生促進化合物 |
| RU2472795C1 (ru) * | 2011-05-20 | 2013-01-20 | Федеральное государственное бюджетное учреждение " Научно-исследовательский институт фармакологии имени В.В. Закусова Российской академии медицинских наук | 2-ЗАМЕЩЕННЫЕ-1,2,4,5-ТЕТРАГИДРО-3H-ПИРРОЛО[1,2-a][1,4]ДИАЗЕПИН-3-ОНЫ |
| MX362184B (es) * | 2012-08-06 | 2019-01-08 | Hoffmann La Roche | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. |
-
2014
- 2014-03-31 BR BR112015020179A patent/BR112015020179A2/pt not_active Application Discontinuation
- 2014-03-31 WO PCT/EP2014/056393 patent/WO2014161801A1/en active Application Filing
- 2014-03-31 TW TW103111999A patent/TW201443056A/zh unknown
- 2014-03-31 CA CA2905270A patent/CA2905270C/en not_active Expired - Fee Related
- 2014-03-31 JP JP2016505780A patent/JP6212623B2/ja active Active
- 2014-03-31 MX MX2015013915A patent/MX2015013915A/es unknown
- 2014-03-31 KR KR1020157026876A patent/KR101767329B1/ko active IP Right Grant
- 2014-03-31 EP EP14717110.2A patent/EP2981538B1/en active Active
- 2014-03-31 CN CN201480019506.5A patent/CN105246895B/zh active Active
- 2014-03-31 RU RU2015144197A patent/RU2628126C2/ru not_active IP Right Cessation
- 2014-04-01 AR ARP140101448A patent/AR095970A1/es unknown
-
2015
- 2015-09-28 US US14/868,059 patent/US9586966B2/en active Active
-
2016
- 2016-02-11 HK HK16101473.6A patent/HK1213553A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR095970A1 (es) | 2015-11-25 |
| CA2905270A1 (en) | 2014-10-09 |
| HK1213553A1 (zh) | 2016-07-08 |
| RU2015144197A (ru) | 2017-05-04 |
| EP2981538A1 (en) | 2016-02-10 |
| TW201443056A (zh) | 2014-11-16 |
| BR112015020179A2 (pt) | 2017-07-18 |
| CA2905270C (en) | 2017-09-05 |
| EP2981538B1 (en) | 2017-08-02 |
| KR101767329B1 (ko) | 2017-08-10 |
| JP6212623B2 (ja) | 2017-10-11 |
| US9586966B2 (en) | 2017-03-07 |
| JP2016515593A (ja) | 2016-05-30 |
| WO2014161801A1 (en) | 2014-10-09 |
| RU2628126C2 (ru) | 2017-08-15 |
| CN105246895B (zh) | 2017-09-22 |
| CN105246895A (zh) | 2016-01-13 |
| US20160016963A1 (en) | 2016-01-21 |
| KR20150122234A (ko) | 2015-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| MX362532B (es) | Derivados de 1,7-naftiridina. | |
| MX2015015052A (es) | Derivados de isoquinolina que estimulan la neurogenesis. | |
| AR093576A1 (es) | Derivados heterociclicos sustituidos | |
| BR112015004942A2 (pt) | benzimidazóis como agentes ativos do snc | |
| MX370661B (es) | Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona. | |
| MX2016008983A (es) | Peliculas termocontraibles de barrera de multicapa pvdc. | |
| MX2015006364A (es) | 1,6-naftiridinas sustituidas. | |
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| EA201590406A1 (ru) | Мочевинные и амидные производные аминоалкилпиперазинов и их применение | |
| PH12015500059B1 (en) | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| BR112015008200A2 (pt) | derivados de imidazopiridina | |
| MX2015013915A (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. | |
| MX2015000629A (es) | Moduladores de benzisoxasol de neurogenesis. | |
| MX2016001528A (es) | Derivados de indol-carboxamida. | |
| AR100532A1 (es) | Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona | |
| TH165816B (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
| TH165816A (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท |